Rhaeos, Inc. Raises $2.2 Million in Oversubscribed Seed Round
Summary
EVANSTON, Ill., Dec. 24, 2021 /PRNewswire/ -- Rhaeos, Inc., a private, clinical stage medical device company developing a platform wireless and non-invasive wearable sensor initially targeting the neurosurgical suite, today announced the successful closing of its oversubscribed $2.2 million seed financing. The round, which brings a total of over $8 million in dilutive and non-dilutive financing to date, includes participation from Creative Ventures, Portal Innovations, Lateral Capital, Cedars-Sinai Accelerator, Kyto Life Science and Technology, Band of Angels, Northwestern Universitys NXT Fund, University of Michigan Social Venture Fund, and private investors. The FlowSense™ platform has the potential to disrupt the wearable medical device space and we are glad to be a part of Rhaeos journey," said Kulika Weizman, Principal at Creative Ventures. The closing of the financing round adds to recent milestones the company accomplished including receiving $4M in grant funding from the NIH, completing the Cedars-Sinai Accelerator program, and initiating their FDA pivotal study. With a market-first principle, Creative Ventures leverages their deep technical and management expertise to support companies addressing labor shortages, climate change, and rising healthcare costs.